Program
moponetug
Also written as “BMS-986446”, “BMS-986446 IV” and “BMS-986446 SC”.
Its studies are mostly in Alzheimer Disease, led by Bristol-Myers Squibb.
Furthest: phase 2, since Feb 13, 20245 company-led studies, 3 open or runningNext primary completion: Dec 17, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 53 open or running | phase 2since Feb 13, 2024 | Oct 10, 2023 | Dec 17, 2026phase 2 · NCT06268886 |
- Named in Bristol-Myers Squibb’s own pipeline as
moponetug
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT06084598 · 24 enrolled · United States
- Feb 13, 2024Phase 2 study in Alzheimer DiseaseNCT06268886 · 310 enrolled · United States, Australia, Belgium and more
- Apr 25, 2025Phase 1 study in Healthy VolunteerNCT06955741 · 46 enrolled · United States
- Aug 19, 2026Phase 1 study in Alzheimer DiseaseNCT07780383 · 84 planned · United States
- Sep 24, 2026Phase 1 study in Healthy VolunteersNCT07852962 · 10 planned
Ahead
- Dec 17, 2026Primary completion: phase 2 study in Alzheimer DiseaseNCT06268886
- Jun 17, 2027Primary completion: phase 1 study in Alzheimer DiseaseNCT07780383
- Jul 18, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07852962
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07852962Healthy Volunteers | 1 | Not yet recruiting | Jul 18, 2027 | 10 |
| NCT07780383Alzheimer Disease · United States | 1 | Recruiting | Jun 17, 2027 | 84 |
| NCT06955741Healthy Volunteer · United States | 1 | Completed | Sep 11, 2025 | 46 |
| NCT06268886Alzheimer Disease · United States, Australia, Belgium and more | 2 | Active, not recruiting | Dec 17, 2026 | 310 |
| NCT06084598Healthy Participants · United States | 1 | Completed | Mar 8, 2024 | 24 |
How it is read
Names in the registry
- “BMS-986446”, 4 entries
- “BMS-986446 IV”, 1 entry
- “BMS-986446 SC”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.